Read by QxMD icon Read

Diabetes & Metabolism

J Jin, W Wang, T Gu, C Chen, J Sun, W Chen, Y Bi, D Zhu
AIM: To investigate the association between serum bilirubin and distal symmetrical polyneuropathy (DSPN) in Chinese patients with type 2 diabetes (T2D). METHODS: A total of 1800 inpatients with T2D (including 68 with 1-year follow-ups) were consecutively enrolled between June 2014 and March 2017. DSPN was diagnosed according to criteria recommended by the Toronto Diabetic Neuropathy Expert Group in 2010. Clinical data were retrospectively collected. RESULTS: Patients with vs...
February 22, 2018: Diabetes & Metabolism
H Qu, Y Qiu, Y Wang, Y Liao, Y Zheng, H Zheng
AIMS: To assess circulating fetuin-B concentrations in subjects with different degrees of glucose tolerance and to analyze the association of fetuin-B concentrations with insulin resistance and the first phase of glucose-stimulated insulin secretion. METHODS: Plasma fetuin-B concentrations were analyzed in 149 subjects with normal glucose tolerance (NGT, n=54), impaired glucose regulation (preDM, n=42) and newly diagnosed type-2 diabetes mellitus (nT2DM, n=53). Intravenous glucose tolerance tests (IVGTTs) and biochemical parameters were also assessed in all participants...
February 22, 2018: Diabetes & Metabolism
M Urpi-Sarda, E Almanza-Aguilera, R Llorach, R Vázquez-Fresno, R Estruch, D Corella, J V Sorli, F Carmona, A Sanchez-Pla, J Salas-Salvadó, C Andres-Lacueva
AIM: To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D. METHODS: A metabolomics analysis using the1 H-NMR-based, non-targeted metabolomic approach was conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of T2D prevalence, respectively...
February 20, 2018: Diabetes & Metabolism
W Masson, M Lobo, D Siniawski, M Huerín, G Molinero, R Valéro, J P Nogueira
BACKGROUND: Cholesteryl ester transfer protein (CETP) inhibitors are a class of drugs that targets the CETP enzyme to significantly increase serum high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) levels. As HDL-C has potential antidiabetic properties, and the beneficial effects of CETP drugs on glucose homoeostasis have not been sufficiently studied, the aims of this study were: (1) to evaluate the effect of CETP inhibitors on the incidence of diabetes; and (2) to assess the association between CETP inhibitor-induced changes in HDL-C levels and incidence of diabetes...
February 20, 2018: Diabetes & Metabolism
R Roussel, R Ritzel, E Boëlle-Le Corfec, B Balkau, J Rosenstock
AIMS: To explore comparative glycaemic control and hypoglycaemia incidence with insulin degludec 100U/mL (IDeg) or insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in trial-level meta-analyses of phase 3a clinical trials including people with type-2 diabetes. METHODS: Meta-analyses of HbA1c , fasting plasma glucose (FPG), average 24h self-measured plasma glucose (SMPG), pre-breakfast SMPG and hypoglycaemia incidence and rate, using data from the BEGIN (IDeg) and EDITION (Gla-300) insulin development programmes, were performed...
February 19, 2018: Diabetes & Metabolism
C C Lim, M W Y Wong, H L Koh, I Y J Mok, Y M Chin, J C J Choo
No abstract text is available yet for this article.
February 15, 2018: Diabetes & Metabolism
D Li, J Yufeng Yang, T Wang, S Shen, H Tang
BACKGROUND: The U.S. Food and Drug Administration recently issued a safety communication requiring new warnings of increased leg and foot amputation risk be added to canagliflozin drug labelling. However, the risk associated with other sodium-glucose co-transporter 2 inhibitors (SGLT2i) remains uncertain. AIM: This meta-analysis aimed to evaluate the potential risks of diabetic foot syndrome (DFS) and amputation associated with SGLT2i. METHODS: Relevant databases were searched from inception to June 14, 2017 to identify randomized controlled trials (RCTs) that evaluated risks of DFS and amputation associated with SGLT2i use...
February 13, 2018: Diabetes & Metabolism
P Barbieux, B György, E Gand, P-J Saulnier, G Ducrocq, J-M Halimi, E Feigerlova, C Hulin-Delmotte, P Llaty, D Montaigne, V Rigalleau, R Roussel, P Sosner, P Zaoui, S Ragot, M Marre, D-A Tregouët, S Hadjadj
No abstract text is available yet for this article.
February 10, 2018: Diabetes & Metabolism
B M Mishriky, R J Tanenberg, K A Sewell, D M Cummings
AIMS: Our aim was to compare Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) to Dipeptidyl peptidase-4 inhibitors (DPP-4i) as add-on therapy to metformin. METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We pooled trials reporting outcomes between 12 and 26 weeks together while trials reporting results ≥52 weeks were pooled together. The primary outcomes were the change in haemoglobin A1c (A1c) at ≤26 and ≥52 weeks...
February 7, 2018: Diabetes & Metabolism
T Kimura, A Obata, M Shimoda, H Hirukawa, Y Kanda-Kimura, Y Nogami, K Kohara, S Nakanishi, T Mune, K Kaku, H Kaneto
AIMS: It is well-known that chronic exposure to large amounts of ligand leads to downregulation of its receptor. It is not known, however, whether a GLP-1R agonist downregulates its receptor. For this reason, our study examined whether GLP-1R expression is reduced after long-term exposure to dulaglutide (Dula) in non-diabetic and diabetic mice. METHODS: Seven-week-old male db/db and db/m mice were given either Dula (0.6mg/kg×2/week) or a control vehicle (CTL) for 17 weeks...
February 6, 2018: Diabetes & Metabolism
Yen-Wei Pai, Ching-Heng Lin, I-Te Lee, Ming-Hong Chang
AIM: The relationship between glycaemic variability and painful diabetic peripheral neuropathy (PDPN) in patients with type 2 diabetes (T2D) is unclear. The aim of this study was to investigate whether variations in fasting plasma glucose (FPG), as represented by the coefficient of variation (CV), were associated with the risk of PDPN in patients with T2D. METHODS: This case-control, retrospective study was conducted at a tertiary care hospital in Taiwan. We enrolled adults with T2D from January 1 through October 31, 2013...
February 4, 2018: Diabetes & Metabolism
E Cosson, B Catargi, G Cheisson, S Jacqueminet, C Ichai, A-M Leguerrier, A Ouattara, I Tauveron, E Bismuth, D Benhamou, P Valensi
No abstract text is available yet for this article.
February 3, 2018: Diabetes & Metabolism
E Y F Wan, E Y T Yu, C S C Fung, W Y Chin, D Y T Fong, A K C Chan, C L K Lam
AIM: The current trend on diabetes management advocates replacing the paradigm from a uniform to an individualized patient-centered haemoglobin A 1c (HbA 1c ) target, but there is no consensus on the optimal HbA 1c level. The study aimed at examining the association between HbA 1c and the risk of cardiovascular diseases (CVD) for diabetic patients with different characteristics, in order to identify patient-centered treatment targets. METHODS: A retrospective cohort study was conducted on 115,782 Chinese adult primary care patients with type 2 diabetes mellitus (DM) but no known CVD history, who were prescribed antidiabetic medications in 2010-2011...
February 3, 2018: Diabetes & Metabolism
Y K Cho, Y M Kang, S E Lee, J Lee, J-Y Park, W J Lee, Y-J Kim, C H Jung
BACKGROUND: This review evaluated the efficacy and safety of a combination therapy comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) in type 2 diabetes. METHODS: A literature search through to May 2017 was carried out of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Studies were eligible if they were randomized controlled trials (RCTs) comparing SGLT2i plus DPP4i (SGLT2i/DPP4i) against DPP4i±placebo or SGLT2i±placebo and published in English...
February 3, 2018: Diabetes & Metabolism
J T H Nielen, P J Emans, B van den Bemt, P C Dagnelie, M T Schram, C D A Stehouwer, N C Schaper, K F M Denissen, F de Vries, A Boonen
No abstract text is available yet for this article.
February 3, 2018: Diabetes & Metabolism
E Cosson, F Gary, M T Nguyen, L Bianchi, D Sandre-Banon, L Biri, Y Jaber, C Cussac-Pillegand, I Banu, S Chiheb, L Carbillon, P Valensi
No abstract text is available yet for this article.
February 2, 2018: Diabetes & Metabolism
S Iceta, B Julien, K Seyssel, S Lambert-Porcheron, B Segrestin, E Blond, P Cristini, M Laville, E Disse
AIM: Eating disorders (EDs), disordered eating (DE) and obesity are thought to have overlapping aetiological processes. DE in obesity can jeopardize weight-loss results, and acyl ghrelin (AG) is a hormone that stimulates food intake and reward processes. The main study objective was to determine whether higher-than-expected concentrations of AG in common obesity are associated with DE symptoms. METHODS: The study population included 84 women, aged 20-55 years, free of established EDs: 55 were severely obese (OB) and 29 were of normal weight (NW)...
January 27, 2018: Diabetes & Metabolism
H S Brink, M Alkemade, A J van der Lely, J van der Linden
No abstract text is available yet for this article.
January 18, 2018: Diabetes & Metabolism
L Nattero-Chávez, M Luque-Ramírez, S Moncayo, S Alonso-Díaz, E Fernández-Durán, S Redondo-López, M García-Ureña, H F Escobar-Morreale
No abstract text is available yet for this article.
January 18, 2018: Diabetes & Metabolism
S Ring, S J Glastras, S L Hocking, S K Seeho, E S Scott, G R Fulcher, R T McGrath
No abstract text is available yet for this article.
January 11, 2018: Diabetes & Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"